PURPOSE: The aim of this study was to investigate the genetic and epigenetic mechanisms contributing to PCDH10 down-regulation in medulloblastoma. We examined the role of PCDH10 as a mediator of medulloblastoma cell proliferation, cell cycle progression, and cell migration. METHODS: We identified a focal homozygous deletion of PCDH10 in medulloblastoma by surveying a cohort of 212 tumours by Affymetrix SNP array analysis. PCDH10 expression was assessed by quantitative reverse transcriptase PCR in a series of 26 tumours. The promoter methylation status of PCDH10 was determined using methylation specific PCR and Sequenom MassCLEAVE analysis. Functional studies examining the role of PCDH10 in medulloblastoma development were performed by re-expression of PCDH10 in the DAOY medulloblastoma cell line, and then, cell proliferation, cell cycle distribution, and cell migration assays were performed. RESULTS: We report a very focal homozygous deletion on chromosome 4q28.3 harbouring the PCDH10 gene. We demonstrate that PCDH10 transcription is down-regulated in 19/26 (73%) of medulloblastomas suggesting that other mechanisms also could be involved in gene repression. We found that DNA hypermethylation contributed to the deregulation of PCDH10 in 11/44 (25%) of medulloblastoma cell lines and primary tumours. Using a stable cell line (DAOY) re-expressing PCDH10, we observed that cell migration was impaired upon restoration of PCDH10 expression. CONCLUSIONS: Our findings suggest that genetic and epigenetic deregulation of PCDH10 occurs in a significant portion of medulloblastoma patients. Failure to express PCDH10 may result in loss of inhibition of cell migration, thereby contributing to medulloblastoma progression.
PURPOSE: The aim of this study was to investigate the genetic and epigenetic mechanisms contributing to PCDH10 down-regulation in medulloblastoma. We examined the role of PCDH10 as a mediator of medulloblastoma cell proliferation, cell cycle progression, and cell migration. METHODS: We identified a focal homozygous deletion of PCDH10 in medulloblastoma by surveying a cohort of 212 tumours by Affymetrix SNP array analysis. PCDH10 expression was assessed by quantitative reverse transcriptase PCR in a series of 26 tumours. The promoter methylation status of PCDH10 was determined using methylation specific PCR and Sequenom MassCLEAVE analysis. Functional studies examining the role of PCDH10 in medulloblastoma development were performed by re-expression of PCDH10 in the DAOY medulloblastoma cell line, and then, cell proliferation, cell cycle distribution, and cell migration assays were performed. RESULTS: We report a very focal homozygous deletion on chromosome 4q28.3 harbouring the PCDH10 gene. We demonstrate that PCDH10 transcription is down-regulated in 19/26 (73%) of medulloblastomas suggesting that other mechanisms also could be involved in gene repression. We found that DNA hypermethylation contributed to the deregulation of PCDH10 in 11/44 (25%) of medulloblastoma cell lines and primary tumours. Using a stable cell line (DAOY) re-expressing PCDH10, we observed that cell migration was impaired upon restoration of PCDH10 expression. CONCLUSIONS: Our findings suggest that genetic and epigenetic deregulation of PCDH10 occurs in a significant portion of medulloblastomapatients. Failure to express PCDH10 may result in loss of inhibition of cell migration, thereby contributing to medulloblastoma progression.
Authors: Yoon-Jae Cho; Aviad Tsherniak; Pablo Tamayo; Sandro Santagata; Azra Ligon; Heidi Greulich; Rameen Berhoukim; Vladimir Amani; Liliana Goumnerova; Charles G Eberhart; Ching C Lau; James M Olson; Richard J Gilbertson; Amar Gajjar; Olivier Delattre; Marcel Kool; Keith Ligon; Matthew Meyerson; Jill P Mesirov; Scott L Pomeroy Journal: J Clin Oncol Date: 2010-11-22 Impact factor: 44.544
Authors: Shawna L Palmer; Tim Hassall; Karen Evankovich; Donald J Mabbott; Melanie Bonner; Cinzia Deluca; Richard Cohn; Michael J Fisher; E Brannon Morris; Alberto Broniscer; Amar Gajjar Journal: Neuro Oncol Date: 2010-08-16 Impact factor: 12.300
Authors: David Ng; Theodora Stavrou; Ling Liu; Michael D Taylor; Bert Gold; Michael Dean; Michael J Kelley; Elizabeth C Dubovsky; Gilbert Vezina; H S Nicholson; Julianne Byrne; James T Rutka; David Hogg; Gregory H Reaman; Alisa M Goldstein Journal: Am J Med Genet A Date: 2005-05-01 Impact factor: 2.802
Authors: Michael D Taylor; Xiaoyun Zhang; Ling Liu; Chi-Chung Hui; Todd G Mainprize; Stephen W Scherer; Brandon Wainwright; David Hogg; James T Rutka Journal: Oncogene Date: 2004-06-03 Impact factor: 9.867
Authors: David J Stewart; Jean-Pierre Issa; Razelle Kurzrock; Maria I Nunez; Jaroslav Jelinek; David Hong; Yasuhiro Oki; Zhong Guo; Sanjay Gupta; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2009-05-26 Impact factor: 12.531
Authors: Yilan Zhen; Carlie L Cullen; Raphael Ricci; Benjamin S Summers; Sakina Rehman; Zubair M Ahmed; Antoinette Y Foster; Ben Emery; Robert Gasperini; Kaylene M Young Journal: Commun Biol Date: 2022-05-30
Authors: Irene Kleinberger; Ellen Sanders; Katrien Staes; Marleen Van Troys; Shinji Hirano; Tino Hochepied; Kelly Lemeire; Liesbet Martens; Christophe Ampe; Frans van Roy Journal: BMC Cancer Date: 2022-04-25 Impact factor: 4.638
Authors: Maria Dobre; Alessandro Salvi; Iulia Andreea Pelisenco; Florina Vasilescu; Giuseppina De Petro; Vlad Herlea; Elena Milanesi Journal: Front Oncol Date: 2021-07-01 Impact factor: 6.244